TAIPEI, Taiwan, January 28, 2026－TaiGen Biotechnology and South Korea-based Boryung Biopharma held a formal signing ceremony in Taipei yesterday (January 28) for the licensing agreement of the novel influenza antiviral drug, TG-1000 (Pixavir).

Following the announcement of the licensing agreement on January 26, representatives from both companies gathered to witness this significant milestone. The agreement was officially signed and sealed by TaiGen Chairman Kuo-Lung Huang and Boryung Biopharma Representative Executive Director Hong-Du Jang, marking the official commencement of the partnership.

During the ceremony, commemorative gifts were exchanged to symbolize the successful collaboration. Following the ceremony, both parties engaged in in-depth discussions regarding future clinical development and commercialization strategies.

Chairman Huang expressed that this in-person signing ceremony has further strengthened the foundation of mutual trust. He looks forward to leveraging Boryung's strong sales capabilities in the Korean respiratory market to bring Pixavir to patients as soon as possible.

TaiGen Chairman Kuo-Lung Huang (left) and Boryung Representative Executive Director Hong-Du Jang (right) signed the licensing agreement.

The leaders of both companies shake hands, marking the official start of the partnership.

Core team members from TaiGen and Boryung gather for a group photo to celebrate the collaboration.